Katy Rezvani, M.D., Ph.D.
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
CAR NK therapy: A new immunotherapy for blood cancers
MD Anderson and Takeda announce collaboration to develop off-the-shelf CAR NK-cell therapies
In the News
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
What is the future of cell therapy in cancer treatment?
NK cells expressing interleukin-21 show promising antitumor activity in glioblastoma cells
CAR NK cells with CD28 costimulation improved cell persistence and antitumor activity
CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies
MD Anderson’s Katy Rezvani, M.D., receives 2023 Honorific Award from the American Society of Hematology
Lost metabolic fitness of CAR NK cells is key mechanism of tumor resistance
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for multiple myeloma
Present Title & Affiliation
Primary Appointment
Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Sally Cooper Murray Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Co-Leadership, T32 Physician-Scientist Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2005 | Imperial College, London, England, PHD, Transplant Immunology |
| 1993 | University College, London, England, MBBS, equivalent to Medicine degree |
| 1990 | University College, London, England, Bachelors of Science, Neuroanatomy/Neuroscience |
Postgraduate Training
| 2004-2007 | Senior Research Fellowship, Stem Cell Allotransplantation Section (SCAT),, Hematology Branch NHLBI, NIH,, Bethesda, MD |
| 1999-2001 | Clinical Fellowship, Hem-Oncology and Bone Marrow Transplant, Hammersmith Hospital, London |
| 1996-1999 | Clinical Fellowship, Hammersmith Hospital, London |
| 1996-1996 | Senior House Officer, University College London Hospital, London |
| 1995-1996 | Clinical Residency, Royal Marsden Hospital, London |
| 1994-1994 | Internship, Mount Vernon Hospital, Northwood |
| 1994-1995 | Clinical Residency, Harefield and Hillingdon Hospitals, Hillingdon |
| 1993-1994 | Internship, University College London Hospital, London |
Board Certifications
| 2017 | American Board of Hematology |
| 2016 | American Board of Internal Medicine |
| 2012 | Royal College of Physicians, London, England, Fellowship of the Royal College of Physicians (FRCP) |
| 2010 | Royal College of Pathologists, Fellowship of the Royal College of Pathologists (FRCPath) |
| 2003 | Membership of the Royal College of Pathologists (MRCPath), England, Boards in Hematology |
| 1996 | Membership of the Royal College of Physicians (MRCP) England, Boards in Internal Medicine |
Experience & Service
Academic Appointments
Section Chief, Cellular Therapy, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2024
Associate Professor, Department of Hematology, Division of and Consultant, Hammersmith Hospital, Imperial College, London, 2011 - 2012
Assistant Professor, Department of Hematology, Division of Clinical Senior Lecturer and Consultant, Hammersmith Hospital, London, England, London, 2008 - 2011
Administrative Appointments/Responsibilities
Director of Translational Research, Department of Stem Cell Transplantation - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2024
Clinical Director of the John Goldman Cellular Therapy Laboratory and Clinical Lead Adult Stem Cell Transplant Program, Hammersmith Hospital, London, 2008 - 2012
Institutional Committee Activities
Member, The University of Texas MD Anderson COVID Taskforce, 2020 - Present
Member, Internal Advisory Board SPORE in Lymphoma at MDACC, 2019 - Present
Member, TRIUMPH mentoring faculty, 2019 - Present
Co Chair, Sabin Physician-Scientist Panel, 2019 - Present
Member, Advisory Board Flow Cytometry and Cellular Imaging Core Facility, 2019 - Present
Member, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Faculty, 2018 - Present
Member, Internal Advisory Board SPORE in Brain Cancer at MDACC, 2018 - Present
Member, Multidisciplinary Research Advisory Committee, 2018 - Present
Lead cellular Therapy Program, Cancer Center Support Grant- Immunology Program, 2017 - Present
Executive Director, Adoptive Cell Therapy Moonshot Platform Steering Committee, 2016 - Present
Member, The University of Texas MD Anderson Cord Blood Bank Steering Committee, 2014 - Present
Member,, GMP Cell Therapy Laboratory Steering Committee, 2012 - Present
Co-Leadership, T32 Physician-Scientist Fellowship Program, 2012 - Present
Honors & Awards
| 2020 | Distinguished Research Faculty Mentor, The University of Texas MD Anderson Cancer Center |
| 2020 | Mentor of the Year Award, The University of Texas MD Anderson Cancer Center - Division of Cancer Medicine |
| 2019 | Sally Cooper Murray Chair in Cancer Research |
| 2019 | Irwin H. Krakoff Award for Excellence in Clinical Research |
| 2019 | Excellence in Oncology Winner Oncology Times |
| 2018 | 2018 R. Lee Clark Prize, University of Texas MD Anderson Cancer Center |
| 2011 | Clinical Excellence Award (level 6), Hammersmith Hospital, London, England |
| 2010 | Clinical Excellence Award (level 3), Hammersmith Hospital, London, England |
| 2007 | Young Investigator Travel Award for best abstract, International Society of Cellular Therapy |
| 2007 | Best scientific abstract award, American Society of Blood and Marrow Transplantation |
| 2006 | Lenfant Biomedical Fellowship Award, National Heart Lung Blood Institute |
| 1993 | Distinction in Medicine, University College, London, England |
| 1993 | Distinction in Surgery, University College, London, England |
| 1993 | Distinction in Pharmacology, University College, London, England |
| 1990 | Intercalated BSc Scholarship, Medical Research Council of UK |
Selected Publications
Peer-Reviewed Articles
- Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
- Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K. Targeting the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest 131(14), 2021. e-Pub 2021. PMID: 34138753.
- Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clin Cancer Res 27(13):3744-3756, 2021. e-Pub 2021. PMID: 33986022.
- Laskowski TJ, Daher M, Basar R, Rezvani K. Avoiding Stops and Overcoming Roadblocks: Considerations for Improving Patient Access to CAR-Based Cell Therapies. Am Soc Clin Oncol Educ Book 41:1-5, 2021. PMID: 33989022.
- Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, Imahashi N, Li L, Lim FLWI, Fathi M, Rezvan A, Mohanty V, Shen Y, Shaim H, Lu J, Ozcan G, Ensley E, Kaplan M, Nandivada V, Bdiwi M, Acharya S, Xi Y, Wan X, Mak D, Liu E, Jiang XR, Ang S, Muniz-Feliciano L, Li Y, Wang J, Kordasti S, Petrov N, Varadarajan N, Marin D, Brunetti L, Skinner RJ, Lyu S, Silva L, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Li H, Fowlkes NW, Chen K, Konopleva M, Champlin RE, Shpall EJ, Rezvani K. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137(5):624-636, 2021. e-Pub 2020. PMID: 32902645.
- Daher M, Rezvani K. Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer. Cancer Discov 11(1):45-58, 2021. e-Pub 2020. PMID: 33277313.
- Laskowski T, Rezvani K. Adoptive cell therapy: Living drugs against cancer. J Exp Med 217(12), 2020. PMID: 33227136.
- Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Hematology Am Soc Hematol Educ Program 2020(1):570-578, 2020. PMID: 33275752.
- Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Blood Adv 4(22):5868-5876, 2020. PMID: 33232480.
- Basar R, Daher M, Uprety N, Gokdemir E, Alsuliman A, Ensley E, Ozcan G, Mendt M, Hernandez Sanabria M, Kerbauy LN, Nunez Cortes AK, Li L, Banerjee PP, Muniz-Feliciano L, Acharya S, Fowlkes NW, Lu J, Li S, Mielke S, Kaplan M, Nandivada V, Bdaiwi M, Kontoyiannis AD, Li Y, Liu E, Ang S, Marin D, Brunetti L, Gundry MC, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Champlin R, Shpall EJ, Rezvani K. Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Adv 4(14):3357-3367, 2020. PMID: 32717029.
- Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses; results from a Phase I/II trial. Clin Cancer Res. e-Pub 2020. PMID: 32299815.
- Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. PMID: 32023374.
- Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani K. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med 379(15):1443-1451, 2018. PMID: 30304652.
- Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol 51:146-153. e-Pub 2018. PMID: 29605760.
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. e-Pub 2018. PMID: 29434334.
- Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity. Leukemia. e-Pub 2017. PMID: 28725044.
- Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K. A subset of virus-specific CD161(+) T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood 129(6):740-758, 2017. e-Pub 2016. PMID: 27821506.
- Mehta RS, Rezvani K. Can we make a better match or mismatch with KIR genotyping?. Hematology Am Soc Hematol Educ Program 2016(1):106-118, 2016. PMID: 27913469.
- Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K. KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood 128(24):2819-2823, 2016. e-Pub 2016. PMID: 27760759.
- Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
- Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26343946.
- Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. BETTER ALLELE-LEVEL MATCHING IMPROVES TRANSPLANT RELATED MORTALITY AFTER DOUBLE CORD BLOOD TRANSPLANTATION. Haematologica. e-Pub 2015. PMID: 26250579.
- Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
- Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, Wolpe S, Blazar BR, Shpall EJ. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood 125(9):1502-6, 2015. e-Pub 2014. PMID: 25428215.
- Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Mehta RS, Chemaly R, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution Following Double Cord Blood Transplantation. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 25708219.
- Ito S, Barrett AJ, Dutra A, Pak E, Miner S, Keyvanfar K, Hensel NF, Rezvani K, Muranski P, Liu P, Melenhorst JJ, Larochelle A. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res 14(1):95-104, 2015. e-Pub 2014. PMID: 25535865.
- Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M, Rezvani K. Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies. Front Immunol 6:36, 2015. e-Pub 2015. PMID: 25699052.
- Bigley AB, Rezvani K, Pistillo M, Reed J, Agha N, Kunz H, O'Connor DP, Sekine T, Bollard CM, Simpson RJ. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Part II: Impact of latent cytomegalovirus infection and catecholamine sensitivity. Brain Behav Immun. e-Pub 2015. PMID: 25578514.
- Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. Stem Cells Transl Med. e-Pub 2014. PMID: 25378655.
- Shah N, Rezvani K, Hosing C, Kebriaei P, Wierda W, Cooper L, Shpall E. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk 14 Suppl:S18-22, 2014. PMID: 25486950.
- Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-Atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplant Outcomes for AML/MDS Patients with Haploidentical versus 10/10 HLA Matched Unrelated and Related Donors. Biol Blood Marrow Transplant. e-Pub 2014. PMID: 25263628.
- Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. Regulatory B-Cells Are Enriched Within the IgM Memory and Transitional Subsets in Healthy Donors but Deficient In Chronic Graft-Versus-Host Disease. Blood. e-Pub 2014. PMID: 25051962.
- Bigley AB, Rezvani K, Chew C, Sekine T, Pistillo M, Crucian B, Bollard CM, Simpson RJ. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Brain Behav Immun 39:160-71, 2014. e-Pub 2013. PMID: 24200514.
- Davies JO, Stringaris K, Barrett JA, Rezvani K. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy. e-Pub 2014. PMID: 24856895.
- Bear AS, Hanley PJ, Bosque DM, Cruz CR, Kaur I, Liu H, Kebriaei P, Hosing C, Rezvani K, Oran B, De Lima MJ, Bollard CM, Shpall EJ. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy. e-Pub 2014. PMID: 24582458.
- Neelakantan P, Rezvani K, May P, Gerrard G, Marco B, Paliompeis C, Reid A, Goldman J, Marin D, Milojkovic D. Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. Br J Haematol 164(4):608-10, 2014. e-Pub 2013. PMID: 24219400.
- Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. e-Pub 2013. PMID: 24169268.
- Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 16(1):90-100, 2014. e-Pub 2013. PMID: 24480547.
- Rezvani K, Barrett J. STAT3: the "Achilles" heel for AML?. Blood 123(1):1-2, 2014. PMID: 24385491.
- Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A, Marin D, Mielke S, Apperley JF, Shpall EJ, Barrett AJ, Rezvani K. Leukemia-induced phenotypic and functional defects in natural killercells predict failure to achieve remission in acute myeloid leukemia. Haematologica. e-Pub 2014. PMID: 24488563.
- Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martín-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 16(1):84-9, 2014. e-Pub 2013. PMID: 24094497.
- Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, O'Brien S, Wierda W, Keating M, Shpall EJ. Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk. e-Pub 2013. PMID: 24502832.
- Innes AJ, Beattie R, Sergeant R, Damaj G, Foroni L, Marin D, Kanfer E, Mielke S, Milojkovic D, Macdonald D, Pavlu J, Rahemtulla A, Roberts I, Slade D, Bray E, Goldman J, Apperley J, Szydlo R, Dazzi F, Rezvani K. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplant 48(10):1324-8, 2013. e-Pub 2013. PMID: 23686098.
- de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, Mielke S, Bazeos A, Stringaris K, Ali S, Milojkovic D, Foroni L, Chaidos A, Cooper N, Gabriel I, Apperley J, Belsey S, Flanagan RJ, Goldman J, Shpall EJ, Kelleher P, Marin D, Rezvani K. Tyrosine Kinase inhibitors impair B cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood 122(2):227-38, 2013. e-Pub 2013. PMID: 23719297.
- Zou J, Rezvani K, Wang H, Lee KS, Zhang D. BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress. Cell Cycle 12(14). e-Pub 2013. PMID: 23797585.
- Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O'Brien S, Clark R, Goldman J, Marin D. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. e-Pub 2013. PMID: 23380743.
- Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J. Cancer Vaccines and T Cell Therapy. Biol Blood Marrow Transplant 19(1 Suppl), 2013. e-Pub 2012. PMID: 23041602.
- Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 8(10):e76781, 2013. e-Pub 2013. PMID: 24204673.
- Ali S, Sergeant R, O'Brien SG, Foroni L, Hedgley C, Gerrard G, Milojkovic D, Stringaris K, Khoder A, Alsuliman A, Gilleece M, Gabriel IH, Cooper N, Goldman JM, Apperley JF, Clark RE, Marin D, Rezvani K. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood 120(3):697-8, 2012. PMID: 22822001.
- Rezvani K, Yong AS, Mielke S, Savani BN, Jafarpour B, Eniafe R, Le RQ, Musse L, Boss C, Childs R, John Barrett A. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother 61(7):1125-36, 2012. e-Pub 2011. PMID: 22198310.
- Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, McDonald D, Marin D, Milojkovic D, Pavlu J, Davis J, Rahemtulla A, Rezvani K, Goldman J, Roberts I, Apperley J, Karadimitris A. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood 119(21):5030-6, 2012. e-Pub 2012. PMID: 22371885.
- Auner HW, Pavlu J, Szydlo R, Giles C, Kanfer E, Macdonald D, Marin D, Milojkovic D, Rezvani K, Goldman JM, Apperley JF, Landgren O, Rahemtulla A. Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. Br J Haematol 157(1):125-7, 2012. e-Pub 2011. PMID: 22050411.
- Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, Rezvani K, Goldman J, Apperley J, Foroni L. BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol 87(3):298-304, 2012. e-Pub 2012. PMID: 22231203.
- Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M, Reid A, Rezvani K, Foroni L, Goldman J, Marin D. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 119(8):1838-43, 2012. e-Pub 2011. PMID: 22174159.
- Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 26(2):296-302, 2012. e-Pub 2011. PMID: 21844874.
- Rezvani K, Kanfer EJ, Marin D, Gabriel I, Rahemtulla A, Taylor A, Macdonald D, Dazzi F, Milojkovic D, Foroni L, Pavlu J, Sargent J, Le Dieu R, Goldman JM, Apperley J, Szydlo R. EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Biol Blood Marrow Transplant 18(2):235-40, 2012. e-Pub 2011. PMID: 21723225.
- Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30(3):232-8, 2012. e-Pub 2011. PMID: 22067393.
- Mielke S, McIver ZA, Shenoy A, Fellowes V, Khuu H, Stroncek DF, Leitman SF, Childs R, Battiwalla M, Koklanaris E, Haggerty J, Savani BN, Rezvani K, Barrett AJ. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant 17(12):1855-61, 2011. e-Pub 2011. PMID: 21684344.
- Rezvani K. CD40-ligand/interleukin-2 vaccines in chronic lymphocytic leukemia: the impact of vaccine design. Cytotherapy 13(9):1029-30, 2011. PMID: 21916777.
- Rezvani K, de Lavallade H. Vaccination strategies in lymphomas and leukaemias: recent progress. Drugs 71(13):1659-74, 2011. PMID: 21902290.
- Rezvani K, de Lavallade H. Improving outcomes in myeloid leukemia patients: does a new DNA vaccine hold the answer?. Expert Rev Vaccines 10(7):933-5, 2011. PMID: 21806391.
- Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 17(5):591-7, 2011. e-Pub 2010. PMID: 20732435.
- Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Patel P, Brett S, Stringaris K, Loucaides E, Howe K, Marin D, Kanfer E, Cooper N, Macdonald D, Rahemtulla A, Atkins M, Danga A, Milojkovic D, Gabriel I, Khoder A, Alsuliman A, Apperley J, Rezvani K. Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. Biol Blood Marrow Transplant 17(5):632-9, 2011. e-Pub 2010. PMID: 20708085.
- Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14):3733-6, 2011. e-Pub 2011. PMID: 21346253.
- Yong AS, Stephens N, Weber G, Li Y, Savani BN, Eniafe R, Keyvanfar K, Kurlander R, Rezvani K, Barrett AJ. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia 25(4):629-37, 2011. e-Pub 2011. PMID: 21252986.
- Rezvani K. Peptide vaccine therapy for leukemia. Int J Hematol 93(3):274-80, 2011. e-Pub 2011. PMID: 21380929.
- Gerrard G, Mudge K, Stewart R, Foskett P, Stevens D, Khorashad JS, Szydlo R, Rezvani K, Marin D, Reid A, Apperley J, Goldman J, Foroni L. Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies. Am J Hematol 86(3):313-5, 2011. e-Pub 2011. PMID: 21328433.
- Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ, Eniafe R, Musse L, Boss C, Kurlander R, Barrett AJ. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 96(3):432-40, 2011. e-Pub 2010. PMID: 21134985.
- de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R, Kanfer E, Macdonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani K. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 96(2):307-14, 2011. e-Pub 2010. PMID: 20971824.
- Rezvani K. Posttransplantation vaccination: concepts today and on the horizon. Hematology Am Soc Hematol Educ Program 2011:299-304, 2011. PMID: 22160049.
- Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, Foroni L, Reid A, de Lavallade H, Rezvani K, Dazzi F, Apperley JF, Goldman JM, Marin D. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood 116(25):5497-500, 2010. e-Pub 2010. PMID: 20833982.
- Gabriel IH, Sergeant R, Szydlo R, Apperley JF, DeLavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, Davis J, MacDonald D, Bua M, Foroni L, Giles C, Milojkovic D, Rahemtulla A, Rezvani K. Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood 116(12):2033-9, 2010. e-Pub 2010. PMID: 20562327.
- Kuwabara A, Babb A, Ibrahim A, Milojkovic D, Apperley J, Bua M, Reid A, Foroni L, Rezvani K, Goldman J, Marin D. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116(6):1014-6, 2010. PMID: 20705771.
- Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Foroni L, Khorashad JS. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 24(6):1243-5, 2010. e-Pub 2010. PMID: 20445576.
- Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381-8, 2010. e-Pub 2010. PMID: 20385986.
- Pavlu J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 115(20):4018-20, 2010. e-Pub 2010. PMID: 20304808.
- Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW, Szydlo R, Bua M, Foroni L, Reid A, Khorashad JS, de Lavallade H, Rezvani K, Paliompeis C, Goldman JM, Marin D. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95(2):224-31, 2010. e-Pub 2009. PMID: 19833633.
- Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 44(12):769-77, 2009. e-Pub 2009. PMID: 19855439.
- Barrett J, Rezvani K. Immunotherapy: Can we include vaccines with stem-cell transplantation?. Nat Rev Clin Oncol 6(9):503-5, 2009. PMID: 19707241.
- Khorashad JS, Wagner S, Greener L, Marin D, Reid A, Milojkovic D, Patel H, Willimott S, Rezvani K, Gerrard G, Loaiza S, Davis J, Goldman J, Melo J, Apperley J, Foroni L. The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. Haematologica 94(6):861-4, 2009. e-Pub 2009. PMID: 19377081.
- Rezvani K, Teng Y, Pan Y, Dani JA, Lindstrom J, García Gras EA, McIntosh JM, De Biasi M. UBXD4, a UBX-containing protein, regulates the cell surface number and stability of alpha3-containing nicotinic acetylcholine receptors. J Neurosci 29(21):6883-96, 2009. PMID: 19474315.
- Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, Savani BN, Keyvanfar K, Li Y, Kurlander R, Barrett AJ. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113(10):2245-55, 2009. e-Pub 2008. PMID: 18988867.
- Rezvani K. PR1 vaccination in myeloid malignancies. Expert Rev Vaccines 7(7):867-75, 2008. PMID: 18767937.
- Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, Goldman JM, Barrett AJ. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 22(9):1721-7, 2008. e-Pub 2008. PMID: 18548092.
- Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol 21(3):437-53, 2008. PMID: 18790448.
- Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR, Fan Y, Gostick E, Price DA, Scotto C, Read EJ, Barrett AJ. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111(8):4392-402, 2008. e-Pub 2007. PMID: 17878399.
- Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 45(1):39-48, 2008. PMID: 18179968.
- Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111(1):236-42, 2008. e-Pub 2007. PMID: 17875804.
- Savani BN, Mielke S, Rezvani K, Montero A, Yong AS, Wish L, Superata J, Kurlander R, Singh A, Childs R, Barrett AJ. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 13(10):1216-23, 2007. e-Pub 2007. PMID: 17889359.
- Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS, Zeilah J, Kurlander R, Srinivasan R, Childs R, Hensel N, Barrett AJ. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 21(10):2145-52, 2007. e-Pub 2007. PMID: 17673900.
- Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, Price DA, Douek DC, Barrett AJ. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 110(6):1924-32, 2007. e-Pub 2007. PMID: 17505014.
- Mielke S, Rezvani K, Savani BN, Nunes R, Yong AS, Schindler J, Kurlander R, Ghetie V, Read EJ, Solomon SR, Vitetta ES, Barrett AJ. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 110(5):1689-97, 2007. e-Pub 2007. PMID: 17478639.
- Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, Kajigaya S, Barrett AJ, Young NS. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood 110(5):1603-6, 2007. e-Pub 2007. PMID: 17463169.
- Yong AS, Rezvani K, Savani BN, Eniafe R, Mielke S, Goldman JM, Barrett AJ. High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood 110(2):770-5, 2007. e-Pub 2007. PMID: 17412886.
- Barrett AJ, Rezvani K. Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol 148(2):189-98, 2007. PMID: 17437417.
- Grube M, Moritz S, Obermann EC, Rezvani K, Mackensen A, Andreesen R, Holler E. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res 13(3):1053-60, 2007. PMID: 17289902.
- Rezvani K, Price DA, Brenchley JM, Kilical Y, Gostick E, Sconocchia G, Hansmann K, Kurlander R, Douek DC, Barrett AJ. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy 9(3):245-51, 2007. PMID: 17464756.
- Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant 12(12):1318-25, 2006. PMID: 17162214.
- Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, Rezvani K, Karimpour S, Childs R, Barrett AJ. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 12(12):1261-9, 2006. PMID: 17162207.
- Li J, Melenhorst J, Hensel N, Rezvani K, Sconocchia G, Kilical Y, Hou J, Curfman B, Major E, Barrett AJ. T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. J Gen Virol 87(Pt 10):2951-60, 2006. PMID: 16963754.
- Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108(4):1291-7, 2006. e-Pub 2006. PMID: 16627754.
- Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS, Leitman S, Read EJ, Childs R, Barrett AJ. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 107(4):1688-95, 2006. e-Pub 2005. PMID: 16131570.
- Barrett J, Rezvani K. Neutrophil granule proteins as targets of leukemia-specific immune responses. Curr Opin Hematol 13(1):15-20, 2006. PMID: 16319682.
- Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, Li J, Mielke S, Douek DC, Barrett AJ. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 11(24 Pt 1):8799-807, 2005. PMID: 16361568.
- Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, Hensel N, Melenhorst J, Li J, Ferrone S, Barrett AJ. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 106(10):3666-72, 2005. e-Pub 2005. PMID: 16046526.
- Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, Rahemtulla A, Samson D, Apperley JF. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 75(5):376-83, 2005. PMID: 16191086.
- Savani BN, Srinivasan R, Espinoza-Delgado I, Dorrance C, Takahashi Y, Igarashi T, Rezvani K, Lundqvist A, Barrett AJ, Childs RW. Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. Lancet Oncol 6(10):809-12, 2005. PMID: 16198987.
- Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, Sconocchia G, Rezvani K, Price DA, Hensel NF, Douek DC, Barrett AJ. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res 11(12):4495-503, 2005. PMID: 15958635.
- Sconocchia G, Provenzano M, Rezvani K, Li J, Melenhorst J, Hensel N, Barrett AJ. CD34+ cells cultured in stem cell factor and interleukin-2 generate CD56+ cells with antiproliferative effects on tumor cell lines. J Transl Med 3(1):15, 2005. e-Pub 2005. PMID: 15831091.
- Sconocchia G, Keyvanfar K, El Ouriaghli F, Grube M, Rezvani K, Fujiwara H, McCoy JP, Hensel N, Barrett AJ. Phenotype and function of a CD56+ peripheral blood monocyte. Leukemia 19(1):69-76, 2005. PMID: 15526027.
- Sconocchia G, Fujiwara H, Rezvani K, Keyvanfar K, El Ouriaghli F, Grube M, Melenhorst J, Hensel N, Barrett AJ. G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte. J Leukoc Biol 76(6):1214-9, 2004. e-Pub 2004. PMID: 15345723.
- Fujiwara H, El Ouriaghli F, Grube M, Price DA, Rezvani K, Gostick E, Sconocchia G, Melenhorst J, Hensel N, Douek DC, Barrett AJ. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood 103(8):3076-83, 2004. e-Pub 2003. PMID: 15070688.
- Grube M, Rezvani K, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. Clin Cancer Res 10(3):1047-56, 2004. PMID: 14871984.
- El-Ouriaghli F, Sloand E, Mainwaring L, Fujiwara H, Keyvanfar K, Melenhorst JJ, Rezvani K, Sconocchia G, Solomon S, Hensel N, Barrett AJ. Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. Blood 102(10):3786-92, 2003. e-Pub 2003. PMID: 12893759.
- Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, Gostick E, Yamada K, Melenhorst J, Childs R, Hensel N, Douek DC, Barrett AJ. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102(8):2892-900, 2003. e-Pub 2003. PMID: 12829610.
- Rezvani K, Mee M, Dawson S, McIlhinney J, Fujita J, Mayer RJ. Proteasomal interactors control activities as diverse as the cell cycle and glutaminergic neurotransmission. Biochem Soc Trans 31(2):470-3, 2003. PMID: 12653665.
- Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, Cullup H, Jarvis M, Middleton PG, Chao N. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program:350-71, 2003. PMID: 14633790.
- Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, Rezvani K, Craddock C, Rassam S, Prentice HG. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. Br J Haematol 115(3):622-9, 2001. PMID: 11736947.
- Pocock CF, Lucas GF, Giles C, Vassiliou G, Cwynarski K, Rezvani K, Apperley JF, Goldman JM. Immune neutropenia associated with anti-human neutrophil antigen-2a (NB1) antibodies following unrelated donor stem cell transplantation for chronic myeloid leukaemia: perpetuation by granulocyte colony-stimulating factor. Br J Haematol 113(2):483-5, 2001. PMID: 11380420.
- Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, Pocock C, Dazzi F, Craddock C, Apperley JF, Cross NC, Goldman JM. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 97(6):1560-5, 2001. PMID: 11238091.
- Pocock C, Szydlo R, Davis J, de La Fuente J, Craddock C, Cwynarski K, Olavarria E, Rezvani K, Kanfer E, Apperley J, Goldman J. Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose. Hematol J 2(4):265-72, 2001. PMID: 11920259.
- Rezvani K, Flanagan AM, Sarma U, Constantinovici N, Bain BJ. Investigation of ethnic neutropenia by assessment of bone marrow colony-forming cells. Acta Haematol 105(1):32-7, 2001. PMID: 11340251.
- Phillips D, Rezvani K, Bain BJ. Exercise induced mobilisation of the marginated granulocyte pool in the investigation of ethnic neutropenia. J Clin Pathol 53(6):481-3, 2000. PMID: 10911809.
Other Articles
- Rezvani K Aurora: a new direction for a new dawn. Blood 119(2):322-3, 2012. PMID: 22247517.
- Rezvani K MAGE: the spell is broken. Clin Cancer Res 17(22):6955-7, 2011. PMID: 22068655.
Abstracts
- Oran B, Cao K, Saliba R, Hosing C, Popat U, de Lima M, Carmazzi Y, Alousi A, Kebriaei P, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Champlin R, Rezvani K, Shpall E. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. American Society of Hematology, 2014.
- Ahmed S, Shpall E, Gulbis A, Jones R, Martinez C, Rondon G, Rezvani K, Oran B, Olson A, Shah N, Parmar S, Popat U, Alousi A, Nieto Y, Hosing C, Bashir Q, Kebriaei P, Qazilbash M, Champlin R, Mulanovich V. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. American Society of Hematology, 2014.
- Shashank S Ghantoji, Sumana Goddu, Swapna Sreenivasula, Dimpy P Shah, Betul Oran, Katy Rezvani, Gabriela Rondon, Elizabeth J. Shpall, Roy F Chemaly. Characteristics and Outcome of Cytomegalovirus (CMV) Infections in 95 Cord Blood Transplant (CBT) Recipients: The MD Anderson Experience. Bio Blood Marrrow Transplant, 2014.
- Anushruti Sarvaria, Ahmad Khoder, Abdullah Alsuliman, Claude Chew, Takuya Sekine, Nichola Cooper, Hugues de Lavallade, Muharrem Muftuoglu, Eric Yvon, Amir Hamdi, Amin M. Alousi, Lisa St. John, David Marin, Kate Stringaris, Enli Liu, Jeffrey Molldrem, Nina Shah, Simrit Parmar, Ian McNiece, Richard E. Champlin, Elizabeth J. Shpall, Katy Rezvani. Immunoregulatory B Cells Are Enriched within Transitional and IgM Memory B Cell Subsets in Healthy Donors but Are Reduced and Functionally Impaired in Patients with Chronic Graft-Versus-Host Disease. Bio Blood Marrrow Transplant, 2014.
- Sai Ravi Pingali, Denai Milton, Antonio di Stasi, Rushang D Patel, Partow Kebriaei, Uday R. Popat, Amin M. Alousi, Paolo Anderlini, Muzaffar H. Qazilbash, Chitra Hosing, Katy Rezvani, Qaiser Bashir, Betul Oran, Elizabeth J. Shpall, Issa F. Khouri, Richard E. Champlin, Stefan O. Ciurea. Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center. Bio Blood Marrow Transplant, 2014.
- Amer Najjar, PhD, Simon N Robinson, PhD, Claude Chew, Li Sufang, Eric Yvon, PhD, Michael W Thomas, PhD, Katy Rezvani, MD, PhD, Elizabeth J. Shpall, MD, PhD and Nina Shah, MD. NK Cells Kill Myeloma Cells By Increasing ER Stress and Decreasing Autophagy Levels. NKG2D and NKP30 Are Involved In These Processes. American Society of Hematology, 2013.
- ate Stringaris, MD, MRCP, FRCPath1*, Takuye Sekine2*, Ahmad Khoder, M.D.3*, Abdullah Alsuliman3*, Pavlu Jiri4*, Anushruthi Sarvaria4*, David Marin5, Jane Apperley6, A. John Barrett, MD7 and Katayoun Rezvani, M.D., PhD8. Defective Natural Killer (NK) Receptor Expression and Effector Function in Acute Myeloid Leukemia Partially Normalize At Remission and Predict Response to Chemotherapy. ASH Annual Meeting 2012 Abstracts, 2012.
- Pratap Neelakantan, MRCP*, Dragana Milojkovic*, Gareth Gerrard, PhD*, Letizia Foroni, Jane Apperley, Richard M Szydlo*, Alistair Reid, PhD*, Marco Bua*, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, MD and David Marin. Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?. ASH Annual Meeting 2012 Abstracts, 2012.
- Pratap Neelakantan, MRCP1*, Gareth Gerrard, PhD1*, Letizia Foroni1, Dragana Milojkovic1*, Jane Apperley1, Richard Szydlo, PhD2*, Marco Bua1*, Alistair G Reid, BSc, PhD1*, Katy Rezvani, MBBS, PhD, MRCP, FRCPath1, John M Goldman, MD1 and David Marin1. Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?. ASH Annual Meeting 2012 Abstracts, 2012.
Book Chapters
- Wickramasinghe SN, Rezvani K. ISCH- The Measurement of Serum Vitamin B 12, Serum Folate and Red Cell Folate. In: Advanced Laboratory Methods in Haematology, 2002.
- Alsuliman A, Garland P, and Rezvani K. The Role of Regulatory T Cells in GVL and GVHD. In: Unknown. Nova Science Publishers.
- Neelakantan P and Rezvani K. : Peptide Vaccines in Myeloid Leukemias. In: Handbook of the Biologically Active Peptides, The 2nd Edition.
Grant & Contract Support
| Title: | Clinical application of genetically engineered cord blood derived natural killer cells |
| Funding Source: | Mike Hogg Foundation |
| Role: | Principal Investigator |
| Title: | Application of natural killer (NK) adoptive immmunotherapy to overcome immunological abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | “A Randomized Phase II Study for the Evaluation of Extracorporeal Photopheresis (ECP) in Combination with Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease (GVHD)” |
| Funding Source: | Therakos |
| Role: | Co-Principal Investigator |
| Title: | Strategic Alliance- Cytomx CAR NK Cells-Project 1 |
| Funding Source: | CYTOMX |
| Role: | Co-Principal Investigator |
| Title: | Enhanced homing of hematopoietic stem cells to marrow with enforced endothelial protein C receptor signaling and fucosylation |
| Funding Source: | SINF |
| Role: | Co-Principal Investigator |
| Title: | Role of the Gastrointestinal Microbiome in Cancer Patient Care |
| Funding Source: | MRP-UTMDACC |
| Role: | Leader Core C |
| Title: | The impact of an ISS mission on the anti-viral and functional properties of NK-cells, T-cells, B-cells and dendritic cell |
| Funding Source: | UH NASA |
| Role: | Co-Investigator |
| Title: | Development of immunotherapeutic strategies to overcome tolerance in leukemia |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | Higher Education Funding Council for England |
| Funding Source: | NHS Clinical Senior lectureship (HEFCE-NHS-CLS) |
| Role: | Award |
| Title: | Immunotherapy in chronic myeloid leukemia |
| Funding Source: | Marie Curie Reintegration Fellowship |
| Role: | Principal Investigator |
| Title: | SPORE in Brain Cancer |
| Funding Source: | NIH/NCI |
| Role: | Project 2 Leader |
| Title: | SPORE in Human Cancers for the Years 2008 and 2009 (PP-1) |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | Cancer Center Support (CORE) |
| Funding Source: | NIH/CCSG |
| Role: | Co-Investigator |
| Title: | The CXCL12-CXCR4-STAT3 pathway and regulation of the CLL immune microenvironment |
| Funding Source: | CLL Global Foundation |
| Role: | Principal Investigator |
| Title: | Activation & Expansion of CLL specific T-cells to study the immune reconstitution following Infusion of CD3/CD28 bead- activated and expanded T cells in patients with chronic lymphocytic leukemia following alemtuzumab based therapy |
| Funding Source: | CLL Foundation |
| Role: | Co-Investigator |
| Title: | Moon Shot Ibrutinib Flagship |
| Funding Source: | CLL Global Research Foundation |
| Role: | Co-Investigator |
| Title: | Curative cell-based therapies for chronic lymphocytic leukemia (CLL) |
| Funding Source: | Sister Institution Network Fund Grant (SINF) |
| Role: | Principal Investigator |
| Title: | Curative Cellular Therapy for CLL Using Off-the-Shelf Cord Blood Derived Natural Killer Cells |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Principal Investigator |
| Title: | MDS/AML Moonshot Cell Therapy Project |
| Funding Source: | UTMDACC |
| Role: | Co-Investigator |
| Title: | CMV Adoptive T cell Therapy for GBM patients |
| Funding Source: | The GBM Moonshot |
| Role: | Principal Investigator |
| Title: | CMV Adoptive T cell Therapy for GBM patients |
| Funding Source: | The Rose Foundation |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified November 04, 2024
Katy Rezvani, M.D., Ph.D.
Katy Rezvani, M.D., Ph.D., with Elizabeth Shpall, M.D.
Members of the Rezvani Lab